论文部分内容阅读
目的:观察天佛参口服液佐治原发性非小细胞肺癌的临床疗效。方法:将100例原发性非小细胞肺癌患者随机分为治疗组50例和对照组50例,治疗组给予天佛参口服液和化疗治疗,对照组单予化疗治疗,4周为1周期,共2个周期,治疗后随访1年,观察两组患者在治疗前、治疗1个、2个疗程的中医症状积分、生活质量评分和无疾病进展生存期。结果:经治后治疗组患者中医症状积分、生活质量评分和无疾病进展生存期均优于对照组,两组比较差异有统计学意义(P<0.05)。结论:天佛参口服液能改善原发性非小细胞肺癌患者化疗时生活质量,并有助于延长生存期。
Objective: To observe the clinical efficacy of Tianfushen oral liquid in treating primary non-small cell lung cancer. Methods: One hundred patients with primary non-small cell lung cancer were randomly divided into treatment group (n = 50) and control group (n = 50). The treatment group was given Tianfushen oral liquid and chemotherapy, while the control group was given chemotherapy alone. , A total of 2 cycles, followed up for 1 year after treatment, observed two groups of patients before treatment, treatment of 1, 2 courses of TCM symptom score, quality of life score and disease-free survival. Results: The TCM symptom score, quality of life score and disease-free survival rate in the treated group were better than those in the control group. There was significant difference between the two groups (P <0.05). Conclusion: Tianfo Shen oral liquid can improve the quality of life of patients with primary non-small cell lung cancer chemotherapy and help to prolong survival.